Skip to main content

Table 2 Summary of within and between group changes on clinical outcomes

From: The feasibility of progressive resistance training in women with polycystic ovary syndrome: a pilot randomized controlled trial

Outcome Measure

PRT (n = 7)

Control (n = 6)

P (between groups)

Effect Size (95 % CI)a

Week 0

Week 12

P

Week 0

Week 12

P

Physiological outcomes

        

 Body weight (kg)

117.4 (36.6)

118.9 (35.4)

0.06

86.0 (26.7)

86.0 (26.8)

0.77

0.01

0.49 [0.61,3.83]

 Body mass index (kg/m2)

41.3 (12.5)

41.7 (12.1)

0.12

33.8 (9.4)

33.8 (9.4)

N/A

0.04

0.37[0.04,1.20]

 Waist Circumference (cm)

123.6 (29.0)

121.5 (29.1)

0.04

95.9 (16.3)

96.6 (17.2)

0.20

0.03

0.40b

 Fat mass (kg)

58.6 (23.3)

59.0 (22.7)

0.50

39.6 (18.3)

40.6 (19.2)

0.24

0.59

0.03[-2.96,1.79]

 Lean mass (kg)

54.7 (12.5)

56.0 (11.3)

0.16

43.9 (10.4)

43.0 (10.0)

0.23

0.01

0.49b

 Fat-free mass (kg)

57.4 (13.6)

58.8 (11.9)

0.13

46.8 (10.8)

46.0 (10.4)

0.26

0.005

0.57b

 Percent body fat (%)

49.7 (8.4)

49.6 (7.6)

0.84

45.2 (10.7)

46.1 (11.2)

0.22

0.36

0.08[-2.66,1.06]

 HbA1c (%)

5.3 (0.4)

5.1 (0.3)

0.037

5.1 (0.3)

5.2 (0.4)

0.24

0.03

0.39b

 Fasting insulin (mU/L)

21 (11)

20 (12)

0.49

9 (5)

10 (6)

0.18

0.24

0.14[-5.50,1.55]

 Fasting glucose (mmol/L)

4.7 (0.8)

4.9 (0.7)

0.03

4.8 (0.4)

4.9 (0.4)

0.71

0.18

0.17[-0.08,0.40]

 HOMA-2

2.62 (1.33)

2.56 (1.43)

0.72

1.19 (0.64)

1.24 (0.71)

0.19

0.27

0.11[-0.65,0.20]

 hsCRP (mg/L)

8.9 (10.7)

8.0 (10.8)

0.38

3.6 (5.1)

3.9 (5.4)

0.12

0.36

0.09[-3.57,1.41]

 Testosterone (nmol/L)

1.5 (0.3)

1.7 (0.5)

0.38

1.7 (0.4)

1.8 (0.3)

0.11

0.91

0.00[-0.44,0.49]

 SHBG (nmol/L)

32 (26)

27 (22)

0.39

47 (25)

47 (25)

0.36

0.25

0.13[-22.58,6.50]

 Free androgen index (%)

8.6 (7.3)

9.8 (6.6)

0.26

4.5 (2.7)

4.7 (2.7)

0.11

0.18

0.17[-0.82,3.83]

Functional outcomes

        

 Upper body strength

190.2 (42.5)

211.5 (52.1)

0.10

141.3 (53.0)

134 (51.0)

0.12

0.06

0.33b

 Lower body strength

258.7 (67.2)

313.2 (90.3)

0.04

221.8 (59.5)

214.8 (64.9)

0.08

0.03

0.45b

Psychological outcomes

        

  PCOSQ

        

 Emotions

4.4 (0.6)

5.1 (0.5)

0.02

3.2 (1.0)

3.1 (0.9)

0.13

0.003

0.60[0.53,1.95]

 Body hair

4.9 (2.0)

4.5 (1.5)

0.37

4.2 (1.7)

4.2 (1.9)

1.0

0.58

0.03[-1.22,0.71]

 Weight

3.3(1.7)

4.1(1.7)

0.06

2.4 (1.5)

2.3 (1.5)

0.70

0.04

0.35[0.03,1.796]

 Infertility problems

0.9 (0.4)

3.5 (0.9)

0.01

1.1 (0.6)

1.9 (1.2)

0.11

0.03

0.41b

 Menstrual problems

4.1 (0.8)

3.9 (0.9)

0.52

3.0 (1.4)

3.0 (1.4)

N/A

0.92

0.00[-1.06,0.96]

  SF-36

        

 Physical Functioning

83.0 (10.4)

89.3 (12.4)

0.05

94.2 (5.8)

90.8 (10.7)

0.18

0.02

0.42b

 Role Physical

21.4 (4.9)

22.3 (3.3)

0.36

17.7 (7.3)

18.8 (7.9)

0.70

0.70

0.02[-4.58,6.58]

 Bodily Pain

67.3 (20.0)

65.3 (18.0)

0.55

45.2 (28.3)

48.8 (22.0)

0.36

0.87

0.00[-10.46,9.00]

 General Health

49.0 (22.3)

54.3 (25.2)

0.27

53.3 (14.4)

49.2 (10.7)

0.19

0.14

0.20[-3.73,22.58]

 Vitality

47.3 (26.2)

56.2 (21.3)

0.12

35.4 (26.4)

30.2 (22.9)

0.29

0.02

0.45b

 Social Functioning

75.0 (14.4)

89.3 (15.2)

0.08

60.4 (18.4)

52.1 (9.4)

0.24

0.002

0.64b

 Role Emotional

18.0 (5.8)

23.0 (4.1)

0.10

9.7 (8.2)

8.3 (7.5)

0.36

0.009

0.51b

 Mental Health

71.4 (22.6)

84.2 (17.2)

0.06

51.7 (20.7)

46.7 (20.7)

0.31

0.009

0.52b

  DASS-21

        

 Depression

10.8 (6.8)

5.4 (5.4)

0.050

12.7 (9.6)

14.7 (9.0)

0.20

0.01

0.50b

 Anxiety

10.3 (5.6)

7.4 (7.0)

0.082

12.3 (11.2)

14.3 (10.8)

0.11

0.03

0.41b

 Stress

12.6 (7.9)

9.7 (9.3)

0.220

21.7 (10.9)

23.0 (11.2)

0.33

0.17

0.18 [-11.11,2.25]

  Exercise Self Efficacy Scale

29.4 (4.7)

31.3 (4.2)

0.095

32.5 (5.3)

30.0 (4.0)

0.10

0.04

0.37b

  1. a = parametric between groups effect sizes and their confidence intervals
  2. b = sample size too small to estimate the confidence intervals
  3. Data reported as mean (standard deviation). Abbreviations: HbA1c hemoglobin A1c, HOMA-2 Homeostatic model of assessment 2, CRP c-reactive protein, SHBG sex hormone binding globulin, PCOSQ Polycystic Ovary Syndrome Questionnaire, SF-36 Medical Outcomes Trust Short Form-36, DASS-21 Depression, Anxiety and Stress Scale 21, Effect size = Cohen’s d